Camille Abboud, MD

Blood and Marrow Transplant & Cellular/Gene Therapy Specialist, Hematologic Oncologist, Medical Oncologist

Camille Abboud

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Video Title Not Available

Watch video on YouTube

Video Title Not Available

Video description not available

Clinical Expertise

  • As a member of our leukemia specialist team, Dr. Abboud cares for patients diagnosed with leukemia through treatment and recovery.

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 1976: American Board of Internal Medicine, Internal Medicine
  • 1978: American Board of Internal Medicine, Hematology

Training

  • 1973 - 1974: Intern, American University Hospital, Beirut, Lebanon
  • 1974 - 1976: Resident, medicine, University of Medicine and Dentistry of New Jersey and Rutgers University, Piscataway, NJ
  • 1976 - 1977: Clinical Fellow, Hematology, University of Rochester, Rochester, NY
  • 1977 - 1979: Research Fellow, Hematology, University of Rochester, Rochester, NY

Education

  • 1974: MD, American University of Beirut, Beirut, Lebanon

Research & Select Publications

Research Interest

Acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disorders, lymphoma, myeloma, chronic lymphoid leukemia, application of chemoimmunotherapy, stem-cell transplantation and targeted therapeutics.

Research Publications

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted Abboud CN, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Authors:

Gyurkocza B, Nath R, Seropian S, one or more additional authors omitted Abboud C, one or more additional authors omitted Giralt S

Journal & Year:

J Clin Oncol | 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Abboud CN, one or more additional authors omitted Walter MJ

Journal & Year:

Leukemia | 2025